

Peter J. Duggan,^{a*} Craig M. Forsyth,^b Andris J. Liepa,^a C. Elisabet Tranberg^a and Andrew C. Warden^a

^aCSIRO Molecular and Health Sciences, Bag 10, Clayton South, Victoria 3169, Australia, and

^bSchool of Chemistry, Monash University, Clayton, Victoria 3800, Australia

Correspondence e-mail: peter.duggan@csiro.au

Key indicators

Single-crystal X-ray study

$T = 123\text{ K}$

Mean $\sigma(\text{C}-\text{C}) = 0.003\text{ \AA}$

R factor = 0.034

wR factor = 0.087

Data-to-parameter ratio = 17.2

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

(4-Bromophenyl)(5-dimethylamino-1,1-dioxo-2-phenyl-1,2-dihydro-1 λ^6 ,2,4,6-thiatriazin-3-yl)-methanone


The title compound, $\text{C}_{17}\text{H}_{15}\text{BrN}_4\text{O}_3\text{S}$, was formed by base-assisted *N*-alkylation of (1,1-dioxo-2-phenyl-2,3-dihydro-1*H*-1 λ^6 ,2,3,5-thiatriazol-4-yl)dimethylamine with *p*-bromophenacyl bromide, followed by ring expansion and aerial oxidation to form an unusual 5-acyl-substituted 3-amino-1,1-dioxo-1,2,4,6-thiatriazine. The thiatriazine ring adopts an envelope conformation, with the S atom displaced by 0.308 (2) Å from the plane of the other five atoms.

Received 24 July 2006

Accepted 7 August 2006

Comment

We have been investigating methods for the preparation of a diverse range of sulfur-containing heterocycles with potential biological activity (Fallon, Jahangiri *et al.*, 2005; Fallon, Francis *et al.*, 2005). We recently reported the structure of a 1,1-dioxo-1,2,4,6-thiatriazine obtained from the base-assisted *N*-alkylation of {2-(3,5-dichlorophenyl)-1,1-dioxo-2,3-dihydro-1*H*-1 λ^6 -[1,2,3,5]thiatriazol-4-yl}dimethylamine with methyl 2-bromopropanoate, followed by a novel base-promoted ring-expansion reaction (Duggan *et al.*, 2005). We report here the structure of the product obtained from a similar reaction, this time between the thiazole, (I), and *p*-bromophenacyl bromide, using a stepwise addition of NaHCO_3 and K_2CO_3 . As in the previous example, the lack of contiguous NMR-responsive nuclei in the product meant that an X-ray structural study was necessary to confirm the identity of the product. Crystals suitable for X-ray analysis were formed by crystallization from dichloromethane/ethyl acetate (1:1). X-ray analysis confirmed that the product was the title 1,2,4,6-thiatriazine dioxide, (II).



The molecular structure of (II) is shown in Fig. 1. The thiatriazine heterocycle adopts an envelope conformation, with atom S1 0.308 (2) Å out of the N2/C2/N3/C1/N1 plane. The N2/S1/N1 plane subtends an angle of 17.5 (1)° with the above plane. This confirms the non-aromatic character of this unsaturated heterocycle and is consistent with that observed in a related 3-methoxy-1,1-dioxo-1,2,4,6-thiatriazine (Hamprecht *et al.*, 1985). The short C2–N4 bond length of 1.328 (3) Å and the coplanarity of the guanidinium-type unit defined by C17/N4/C16/C2/N2/N3 indicate significant conju-




Figure 1
View of the molecular structure of (II) (50% probability displacement ellipsoids) showing the atom numbering scheme.




Figure 2
View of the crystal structure of (II) showing π -stacking interactions. H atoms have been omitted.

gation in this region. The shorter S1–N2 bond length of 1.561 (2) Å suggests that this bond is also partially conjugated with the above system. A similar effect is not observed with the S1–N1 bond, presumably because the torsion angle N3–C1–C3–O3 is 95.5 (2)°, thus limiting conjugation. This is also consistent with the unusually long bond length for adjacent Csp^2 atoms of 1.528 (3) Å, seen for the C1–C3 bond.

Interestingly, in the crystal structure of (II), there appears to be intermolecular π stacking occurring between the guanidinium region centred on C2, N4 in another molecule and the

non-brominated phenyl ring of a third molecule, as indicated in Fig. 2.

A publication detailing the scope of the uncommon ring-expansion reaction that produced compound (II) is currently in preparation.

Experimental

The title compound was prepared from the phenylthiazole dioxide, (I) (100 mg, 0.42 mmol), by an initial 5 min treatment with NaHCO_3 (42 mg, 0.50 mmol) in *N,N*-dimethylformamide (1 ml) at room temperature, followed by the addition of *p*-bromophenacyl bromide (139 mg, 0.50 mmol) dissolved in *N,N*-dimethylformamide (0.5 ml). The mixture was stirred at room temperature for 2 h. K_2CO_3 (71 mg, 0.51 mmol) was then added and stirring was continued for a further 5 d. The reaction mixture was diluted with water (5 ml) and diethyl ether (2 ml), and then extracted with CHCl_3 (3 \times), and the combined organic layers were washed with water (2 \times), dried (MgSO_4), filtered and concentrated to yield the product (102 mg, 56%) as an orange foam. A sample was further purified by radial chromatography using a hexane/ethyl acetate solvent gradient then recrystallized from dichloromethane/ethyl acetate (1:1) to give colourless needles suitable for X-ray analysis. m/z (APCI, +ve, $\text{MeOH}:\text{CH}_3\text{CN}:\text{H}_2\text{O}$ 2:1:1) 435, 437 ($M+1$). Analysis, calculated for $\text{C}_{17}\text{H}_{15}\text{BrN}_4\text{O}_3\text{S}$: C 46.91, H 3.47, N 12.87, S 7.37%; found: C 47.17, H 3.53, N 12.89, S 7.08%. M.p. 427–429 K.

Crystal data

$\text{C}_{17}\text{H}_{15}\text{BrN}_4\text{O}_3\text{S}$
 $M_r = 435.3$
Monoclinic, $C2/c$
 $a = 23.4478$ (3) Å
 $b = 10.0971$ (2) Å
 $c = 15.2847$ (2) Å
 $\beta = 101.518$ (1)°
 $V = 3545.85$ (10) Å³

$Z = 8$
 $D_x = 1.631$ Mg m⁻³
Mo $K\alpha$ radiation
 $\mu = 2.46$ mm⁻¹
 $T = 123$ (2) K
Block, colourless
0.25 \times 0.25 \times 0.1 mm

Data collection

Nonius KappaCCD diffractometer
Absorption correction: empirical
(using intensity measurements)
(*SORTAV*; Otwinowski & Minor, 1997)
 $T_{\min} = 0.578$, $T_{\max} = 0.791$

18424 measured reflections
4071 independent reflections
3411 reflections with $I > 2\sigma(I)$
 $R_{\text{int}} = 0.042$
 $\theta_{\max} = 27.5^\circ$

Refinement

Refinement on F^2
 $R[F^2 > 2\sigma(F^2)] = 0.035$
 $wR(F^2) = 0.087$
 $S = 1.05$
4071 reflections
237 parameters
H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.044P)^2 + 4.5742P]$
where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\max} = 0.001$
 $\Delta\rho_{\max} = 1.15$ e Å⁻³
 $\Delta\rho_{\min} = -0.60$ e Å⁻³

H atoms were placed in calculated positions, with C–H distances ranging from 0.95 to 0.98 Å, and included in the refinement in the riding-model approximation with $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$, or $U_{\text{iso}}(\text{H}) = 1.5U_{\text{eq}}(\text{C})$ for methyl H atoms. The highest residual density peak is located 0.93 Å from atom Br1.

Data collection: *COLLECT* (Nonius, 2000); cell refinement: *DENZO-SMN* (Otwinowski & Minor, 1997); data reduction: *X-SEED* (Barbour, 2001); program(s) used to solve structure:

SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *X-SEED* and *POV-RAY* (Persistence of Vision, 2004); software used to prepare material for publication: *WinGX* (Farrugia, 1999).

The Australian Research Council is acknowledged for funding the purchase of the diffractometer used in this study.

References

- Barbour, L. J. (2001). *J. Supramol. Chem.* **1**, 189–191.
- Duggan, P. J., Fallon, G. D. & Liepa, A. J. (2005). *Acta Cryst.* **E61**, o2694–o2695.
- Fallon, G. D., Francis, C. L., Johansson, K., Liepa, A. J. & Woodgate, R. C. J. (2005). *Aust. J. Chem.* **58**, 891–900.
- Fallon, G. D., Jahangiri, S., Liepa, A. J. & Woodgate, R. C. J. (2005). *Aust. J. Chem.* **58**, 332–338.
- Farrugia, L. J. (1999). *J. Appl. Cryst.* **32**, 837–838.
- Hamprecht, G., Acker, R.-D. & Hädicke, E. (1985). *Liebigs Ann. Chem.* pp. 2363–2370.
- Nonius (2000). *COLLECT*. Nonius BV, Delft, The Netherlands.
- Otwinowski, Z. & Minor, W. (1997). *Methods in Enzymology*, Vol. 276, *Macromolecular Crystallography*, Part A, edited by C. W. Carter Jr & R. M. Sweet, pp. 307–326. New York: Academic Press.
- Persistence of Vision (2004). Persistence of Vision Raytracer. Persistence of Vision Pty. Ltd, Williamstown, Victoria, Australia.
- Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.